Biogen, Stoke Therapeutics and epilepsy

Biogen continues dealmaking buzz with Stoke Therapeutics
Stoke Therapeutics Inc. (Nasdaq: STOK) has pulled in Biogen (Nasdaq: BIIB) to help it develop and commercialize a treatment it’s working on for Dravet syndrome, a rare, debilitating form of epilepsy that affects children.
Stoke Therapeutics and Biogen in pact for treatment for severe form of childhood epilepsy
Stoke Therapeutics Inc. and Biogen Inc. said Tuesday they are entering a collaboration to develop and commercialize a treatment for Dravet syndrome, a severe form of epilepsy that starts in childhood.
Biogen partners with Stoke Therapeutics to sell severe epilepsy drug
From my colleague Adam Feuerstein: Biogen and Stoke Therapeutics have signed a partnership agreement to co-develop and sell Stoke’s experimental treatment for Dravet syndrome, a severe form of epilepsy, outside the U.S., the companies said this morning.
Biogen Inks Deal to Commercialize Stoke Therapeutics' Dravet Syndrome ASO; Stoke Retains US Rights
Biogen will receive rights to commercialize zorevunersen outside the US, Canada, and Mexico, paying $165 million upfront and other milestone payments.
Biogen, Stoke Therapeutics Set Dravet Syndrome Collaboration
Biogen and Stoke Therapeutics have agreed to collaborate on Stoke's proposed zorevunersen treatment for the severe genetic epilepsy Dravet syndrome in a deal potentially worth hundreds of millions of dollars to Stoke.
Biogen partners with Stoke Therapeutics on drug for severe epilepsy
Biogen and Stoke Therapeutics have signed a deal to co-develop and sell Stoke’s experimental drug for Dravet syndrome, outside the U.S.
Biogen, Stoke Therapeutics announce zorevunersen commercialization agreement
Biogen (BIIB) and Stoke Therapeutics (STOK) announced a collaboration for the development and commercialization of zorevunersen, a potential
The Harvard Crimson10d
Cambridge Biopharma Firm Sage Therapeutics Sues Partner Biogen After Buyout Offer
Cambridge-based biopharmaceutical company Sage Therapeutics filed a lawsuit against their partner, the biotechnology company ...
Biogen details pipeline culling as it looks for more deals like HI-Bio acquisition
Biogen Inc. CEO Christopher Viehbacher gave investors an overview of what type of deals the company is looking for Wednesday ...
Biogen’s stock slides on soft guidance and a decline in sales of MS drugs
Biogen Inc.’s stock tumbled 7% Wednesday, after the biotech beat fourth-quarter earnings estimates but offered guidance ...
Business Wire4d
Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with ...
CAMBRIDGE, Mass. & BEDFORD, Mass.--(BUSINESS WIRE)--Biogen Inc. (Nasdaq: BIIB) and Stoke Therapeutics, Inc. (Nasdaq: STOK) today announced a collaboration for the ...
Biogen Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
Analysts expect the Cambridge, Massachusetts-based company to report quarterly earnings at $3.36 per share, up from $2.95 per ...
Morningstar3d
Stoke Therapeutics and Biogen in pact for treatment for severe form of epilepsy
based Stoke (STOK) will retain exclusive rights for the treatment called zorevunersen in the U.S., Canada and Mexico, while Cambridge, Mass.-based Biogen (BIIB) will received exclusive rights to ...